NOVA · 101MS329
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A randomized, controlled, open-label, rater-blinded phase 3b study assessing the efficacy, safety and tolerability of six-week extended-interval natalizumab (BG00002) dosing versus continued four-week standard-interval dosing in patients with relapsing-remitting multiple sclerosis. EudraCT: 2018-002145-11.
Sponsor: BIOGEN
Phase: III
Area: Neuroimmunology